Biocon Biologics Malaysian arm enters Malaysia Book of Records
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins.
Bengaluru: Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics Ltd (BBL), has announced that it has entered the prestigious Malaysia Book of Records. The 562,000 sq. ft. facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR, which officially recognizes record-creating and record-breaking achievements in the fields of human endeavour, building & structures, transportation, arts & entertainment, business, sports & games, science & technology, nature etc. in Malaysia.
Malaysia Book of Records (MBR) is the official, record-keeping body of Malaysia that recognizes record-holders, record-breakers and record-creators in the country.
Kiran Kumar Gandhirajan, Site Head, Malaysia, said: "We are extremely proud and honoured to be named in the Malaysia Book of Records, which is a recognition of the scale of our operations in the region. As the only insulin manufacturer in Malaysia, we have been able to achieve insulin self-sufficiency and improve insulin access while providing savings to our partner, Ministry of Health (MoH), Malaysia. Through the insulins manufactured at this facility, Biocon Biologics is also making a difference to the lives of millions of people with diabetes worldwide in line with our aspiration of taking our biosimilar insulins to 'one in five' insulin-dependent patients."
"I would like to acknowledge the remarkable work being done by the team in Malaysia to address the global need for high quality insulins at affordable prices through our Center of Excellence (CoE) for insulins in Malaysia," he added.
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins.
More recently, Biocon's biosimilar insulin Glargine made at Malaysia received U.S. FDA approval as the 'first interchangeable biosimilar'. Commercial operations at the facility commenced in 2016 when Biocon Biologics' recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia.
Read also: Biocon arm bags EU GMP certification for new Bengaluru facility
